Hello everyone, I’m excited to be helping to facilitate the discussion! Thanks to the authors and experts for participating, and congratulations on this breakthrough study.
The idea of using immunotherapy to treat advanced RCC is not a novel concept . For example, IL-2 was previously used to treat metastatic RCC with disappointing results. What sets nivolumab (an anti-PD1 inhibitor) apart from other therapies used in the treatment of advanced metastatic RCC?